These results suggest that recognition of aberrantly glycosylated antigens in tumor cells by the mMGL1 receptor could activate the intracellular signaling of MAPKs, such as ERK1/2, thereby promoting inflammation and MDSCs differentiation. This evidence concerns the gene MAPK3 and neoplasm.